A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Colorectal Cancer|Triple Negative Breast Cancer|Pancreatic Cancer|Non-Small Cell Lung Cancer|Head and Neck Cancer|Ovarian Cancer|Lymphoma|Sarcoma|Bladder Cancer|Melanoma|IDH1 Mutated Solid Tumors|IDH1 Mutated or MGMT Methylated Recurrent HGG (Not Recruiting)
Interventions: BIOLOGICAL: Toca 511|DRUG: Toca FC
Sponsor: Tocagen Inc.